You are receiving this message since your browser does not support Java Script or you have Java Scripts disabled. The following disclaimer is provided as an alternative to the information that would normally be seen on your monitor when you click on a link to a non-federal site.

"You are now leaving the NIDDK website. The NIDDK is not responsible for the content of web pages found on this linked website. Links to nonfederal organizations are provided solely as a service to our users. These links do not indicate an endorsement of these organizations by NIDDK or the federal government."

Type 1 Diabetes (T1D) Special Statutory Funding Program

Research Consortia and Clinical Trials Networks

Standardization Programs

Blood Glucose Monitoring
The goal of the program is to evaluate and determine the variability among blood glucose monitoring systems and to develop a standardization program to improve and normalize results among these systems. More Information

C-peptide Standardization Program
Clinical trials of agents to preserve beta cell function in new onset type 1 diabetes will use C-peptide as an outcome measure that indicates insulin production. The C-peptide standardization program is supported to establish reliability in results and facilitate the conduct of international clinical trials. More Information

Diabetes Autoantibody Standardization Program (DASP)
The fundamental aim of DASP is to improve the measurements of the autoantibodies predictive of type 1 diabetes. More Information

Improving the Clinical Measurement of HbA1C
The goal of this project is to improve HbA1c measurements and data interpretation across clinical systems and national harmonization projects. More Information

Return to Research Consortia and Clinical Trials Networks Topic List



Last Updated: June 30, 2008

General Inquiries may be addressed to:
Office of Communications and Public Liaison
NIDDK, NIH
Building 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560 USA
For information about NIDDK programs: 301.496.3583